Evidence map›Paper›PMID 37973692›Full record

ArticleTissue engineering and regenerative medicine2024

Preliminary Investigation on Efficacy and Safety of Substance P-Coated Stent for Promoting Re-Endothelialization: A Porcine Coronary Artery Restenosis Model.

Dae Sung Park, Seok Oh, Yu Jeong Jin, Mi Hyang Na, Munki Kim, Jeong Ha Kim, Dae Young Hyun, Kyung Hoon Cho, Young Joon Hong, Ju Han Kim and 12 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tissue engineering and regenerative medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 4 countries.

Dae Sung ParkThe Korea Cardiovascular Stent Research Institute, Chonnam National University, Gwangju, Korea.ORCID 0000-0002-9948-7546
Seok OhThe Korea Cardiovascular Stent Research Institute, Chonnam National University, Gwangju, Korea.
Yu Jeong JinThe Korea Cardiovascular Stent Research Institute, Chonnam National University, Gwangju, Korea.
Mi Hyang NaThe Korea Cardiovascular Stent Research Institute, Chonnam National University, Gwangju, Korea.
Munki KimThe Korea Cardiovascular Stent Research Institute, Chonnam National University, Gwangju, Korea.
Jeong Ha KimThe Korea Cardiovascular Stent Research Institute, Chonnam National University, Gwangju, Korea.
Dae Young HyunThe Korea Cardiovascular Stent Research Institute, Chonnam National University, Gwangju, Korea.
Kyung Hoon ChoThe Korea Cardiovascular Stent Research Institute, Chonnam National University, Gwangju, Korea.
Young Joon HongThe Korea Cardiovascular Stent Research Institute, Chonnam National University, Gwangju, Korea.
Ju Han KimThe Korea Cardiovascular Stent Research Institute, Chonnam National University, Gwangju, Korea.
Youngkeun AhnThe Korea Cardiovascular Stent Research Institute, Chonnam National University, Gwangju, Korea.
Manuel Hermida-PrietoInstituto de Investigación Biomédica de A Coruña (INIBIC), Universidade da Coruña (UDC), A Coruña, Spain.
José Manuel Vázquez-RodríguezInstituto de Investigación Biomédica de A Coruña (INIBIC), Universidade da Coruña (UDC), A Coruña, Spain.
Juan Luis Gutiérrez-ChicoBundeswehrzentralkrankenhaus (Federal Army Central Military Hospital), Koblenz, Germany.
Luis Mariñas-PardoFacultad de Ciencias de La Salud, Universidad Internacional de Valencia (VIU), Valencia, Spain.
Kyung Seob LimFuturistic Animal Resource & Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Korea.
Jun-Kyu ParkCGBio Co. Ltd., Seoul, Korea.
Dae-Heung ByeonCGBio Co. Ltd., Seoul, Korea.
Young-Nan ChoDepartment of Clinical Laboratory Medicine, Chonnam National University Hospital, Gwangju, Korea.
Seung-Jung KeeDepartment of Clinical Laboratory Medicine, Chonnam National University Hospital, Gwangju, Korea.
Doo Sun Sim *The Korea Cardiovascular Stent Research Institute, Chonnam National University, Gwangju, Korea. true1021@naver.com.
Myung Ho Jeong *The Korea Cardiovascular Stent Research Institute, Chonnam National University, Gwangju, Korea. myungho@chollian.net.
Chonnam National University · KRChonnam National University Hospital · KRUniversidade da Coruña · ESKorea Research Institute of Bioscience and Biotechnology · KRUniversidad Alfonso X el Sabio · ESValencian International University · ES

Funding

Korea Medical Device Development Fund 1711137864Korea Medical Device Development Fund 1711138916Korea Medical Device Development Fund KMDF_PR_20200901_0005Korea Medical Device Development Fund KMDF_PR_20200901_0280YOOYOUNG Pharm (KR) 2018-3231
6 · The paper itself

Abstract

backgroundCurrent polymer-based drug-eluting stents (DESs) have fundamental issues about inflammation and delayed re-endothelializaton of the vessel wall. Substance-P (SP), which plays an important role in inflammation and endothelial cells, has not yet been applied to coronary stents. Therefore, this study compares poly lactic-co-glycolic acid (PLGA)-based everolimus-eluting stents (PLGA-EESs) versus 2-methacryloyloxyethyl phosphorylcholine (MPC)-based SP-eluting stents (MPC-SPs) in in-vitro and in-vivo models.

methodsThe morphology of the stent surface and peptide/drug release kinetics from stents were evaluated. The in-vitro proliferative effect of SP released from MPC-SP is evaluated using human umbilical vein endothelial cell. Finally, the safety and efficacy of the stent are evaluated after inserting it into a pig's coronary artery.

resultsSimilar to PLGA-EES, MPC-SP had a uniform surface morphology with very thin coating layer thickness (2.074 μm). MPC-SP showed sustained drug release of SP for over 2 weeks. Endothelial cell proliferation was significantly increased in groups treated with SP (n = 3) compared with the control (n = 3) and those with everolimus (n = 3) (SP: 118.9 ± 7.61% vs. everolimus: 64.3 ± 12.37% vs. the control: 100 ± 6.64%, p < 0.05). In the animal study, the percent stenosis was higher in MPC-SP group (n = 7) compared to PLGA-EES group (n = 7) (MPC-SP: 28.6 ± 10.7% vs. PLGA-EES: 16.7 ± 6.3%, p < 0.05). MPC-SP group showed, however, lower inflammation (MPC-SP: 0.3 ± 0.26 vs. PLGA-EES: 1.2 ± 0.48, p < 0.05) and fibrin deposition (MPC-SP: 1.0 ± 0.73 vs. PLGA-EES: 1.5 ± 0.59, p < 0.05) around the stent strut. MPC-SP showed more increased expression of cluster of differentiation 31, suggesting enhanced re-endothelialization.

conclusionCompared to PLGA-EES, MPC-SP demonstrated more decreased inflammation of the vascular wall and enhanced re-endothelialization and stent coverage. Hence, MPC-SP has the potential therapeutic benefits for the treatment of coronary artery disease by solving limitations of currently available DESs.

Indexed as

Coronary RestenosisDrug-Eluting StentsPercutaneous Coronary InterventionAnimalsCoronary VesselsEverolimusHumansHuman Umbilical Vein Endothelial CellsInflammationStentsSubstance PSwineEverolimusSubstance PAnimal researchCoronary artery diseaseRe-endothelializationStentsSubstance P

Identifiers

PMID37973692
PMCPMC10764706
OpenAlexW4388728514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.